Zadium Duo Tablet 12.5/500 mg (Empagliflozin, Metformin Hydrochloride)

Adult dose

The recommended dosage for this medication is 1 tablet per dose, taken twice a day. The dosing should be determined considering the current treatment regimen, efficacy, and tolerability of each patient, ensuring that the maximum recommended daily dosages of empagliflozin 25 mg and metformin 2000 mg are not exceeded. For patients unable to achieve adequate blood glucose control with metformin alone or in combination with other medications such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily amount 10 mg) along with the existing metformin dosage.

This medication is used for diabetes management and contains two active components. Firstly, metformin hydrochloride lowers blood glucose but may lead to a rare side effect known as severe lactic acidosis, requiring caution. Secondly, empagliflozin increases glucose excretion in the urine, which may elevate the risk of urinary tract infections or genital infections. This medication should not be used in patients with severely impaired kidney function, acute infections, heart failure, or other serious conditions. It is also not recommended for pregnant or nursing women or patients with impaired liver function. During treatment, kidney function should be regularly monitored, especially in elderly patients or those with mildly impaired kidney function, who require closer observation. Caution must be taken to avoid fluid loss due to dehydration, severe vomiting, or diarrhea during treatment; if such symptoms occur, discontinue the medication and consult a physician. If taken alongside other diabetes medications such as insulin or sulfonylureas, there may be an increased risk of hypoglycemia, necessitating dosage adjustments. Serious metabolic disturbances such as lactic acidosis and ketoacidosis may occur. If symptoms like malaise, muscle pain, shortness of breath, or abdominal pain arise, inform healthcare personnel immediately. It is advisable to avoid alcohol consumption during treatment for blood glucose control, and to temporarily suspend use before surgeries or tests involving iodine contrast agents. Increased urination or symptoms of urinary tract infections or genital infections may occur during treatment; notify healthcare personnel if these symptoms appear. The safety of this medication in pediatric patients has not been established and is not recommended for those under 18. Furthermore, elderly patients require careful management due to the risks of kidney function decline and fluid loss. In cases of overdose, there is a risk of hypoglycemia or lactic acidosis, requiring immediate hospital treatment, and possible blood dialysis. This medication should be stored out of reach of children and kept in its original container for safety.

Serious side effects

Urticaria, angioedema, severe swelling, urinary sepsis, pyelonephritis, perineal necrosis, lactic acidosis, ketoacidosis, severe skin reactions (such as severe rash with fever, blisters, skin peeling, mouth/eye mucosa pain), shortness of breath, asthma attacks, respiratory distress, liver dysfunction (jaundice, yellowing of skin or eyes, general malaise), sudden and severe headache, seizures, altered consciousness, visual disturbances, paralysis.

Mild side effects

• Hypoglycemia
• urinary tract infections
• genital infections
• increased urination
• nausea
• vomiting
• diarrhea
• abdominal pain
• loss of appetite
• constipation

This medication must be stored in a sealed container to avoid exposure to air or moisture, and the storage temperature should be maintained between 1 to 30 degrees Celsius (room temperature). This is essential to preserve the medication's effectiveness and ensure its safe use.

Appearance

Light brownish purple, oval, biconvex film-coated tablet

Package unit

60 tablets/box (10 tablets/PTP x 6), 10 tablets/box (10 tablets/PTP x 1), 60 tablets/bottle, 30 tablets/bottle